Clinical Pipeline

Click on the study to learn more

Phase I
Phase II
Phase III
Registration Trial

Metastatic Melanoma

STATUS: Phase II

Metastatic Melanoma

Phase II study to assess the safety and efficacy of multiple treatment cycles of ImmunoPulse™ IL-12 monotherapy in patients with in-transit cutaneous and subcutaneous metastatic melanoma. Patients are currently being enrolled into an extension arm of the study to evaluate a new six-week treatment cycle.

Melanoma
Combination Study

STATUS: Phase II

Melanoma
Combination Study

Phase II study to evaluate the safety and efficacy of ImmunoPulse™ IL-12 in combination with Merck’s KEYTRUDA® (pembrolizumab) in patients with advanced metastatic melanoma.

Head & Neck Cancer

STATUS: Phase II

Head & Neck Cancer

Phase II study to evaluate the safety and efficacy of ImmunoPulse™ IL-12 in patients with advanced recurrent squamous cell carcinoma of the head and neck (HNSCC).

Triple Negative
Breast Cancer

STATUS: Phase II

Triple Negative
Breast Cancer

Phase II pilot study to evaluate the ability of ImmunoPulse™ IL-12 to promote an immunogenic tumor microenvironment in advanced recurrent triple negative breast cancer (TNBC).

Canine Soft
Tissue Sarcoma

STATUS: Phase I

Canine Soft
Tissue Sarcoma

Collaboration with UC Davis School of Veterinary Medicine to test ImmunoPulse™ IL-12 as an immunotherapy in dogs with soft tissue sarcoma.

Orange = Monotherapy with IL-12 | Green = Combination Therapy

Learn more about our current clinical trials.LEARN MORE